Aerie Pharmaceuticals reported $-35891000 in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Aerie Pharmaceuticals AERI:US $ -35.89M 81.42M
Alimera Sciences ALIM:US $ -5.96M 1.85M
Amarin AMRN:US $ -31.56M 46.26M
Cara Therapeutics CARA:US $ -27749000 5.63M
Coherus Biosciences CHRS:US $ -96.08M 50.36M
Endo International Ordinary Shares ENDP:US $ -71.97M 490.09M
Horizon Pharma HZNP:US $ 204.26M 31.08M
Insmed INSM:US $ -94621000 18.36M
Merk MRK:US $ 4310M 552M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Novartis NOVN:VX SF 2222M 14086M
Ophthotech OPHT:US $ -34.54M 1.5M
Pacira Pharmaceuticals PCRX:US $ 6.83M 11.96M
Regeneron Pharmaceuticals REGN:US $ 973.5M 1255.5M
Revance Therapeutics RVNC:US $ -64.34M 1.24M
Supernus Pharmaceuticals SUPN:US $ 25.62M 23.17M
Teva Pharmaceutical Industries TEVA:US $ -955M 797M
Valeant Pharmaceuticals VRX:CN $ -69M 138M
Zoetis ZTS:US $ 595M 181M